Fundraising FoxSynartro
Uppsala, SE · 1 known investors
Find your way into Synartro
Sign up to see every warm intro you have to Synartro
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Synartro team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Synartro is a clinical-stage Swedish life science company developing intra-articular injection treatments that chemically bind proven drugs to a patented hyaluronan-based local injection technology for sustained drug release without systemic side effects. Its lead candidate SYN321, a slow-release diclofenac injection, is in development as a second-line treatment for symptomatic knee osteoarthritis.
Founders & leadership
FL
Fredrik LehmannFounder & Chairman
MH
Magnus HurstCFO & Acting CEO
AB
Antonio Bermejo GómezChief Development Officer
Investors · 1
Frequently asked questions
- What does Synartro do?
- Synartro is a clinical-stage Swedish life science company developing intra-articular injection treatments that chemically bind proven drugs to a patented hyaluronan-based local injection technology for sustained drug release without systemic side effects. Its lead candidate SYN321, a slow-release diclofenac injection, is in development as a second-line treatment for symptomatic knee osteoarthritis.
- Who are Synartro's investors?
- Synartro's investors include Sciety.
- Where is Synartro headquartered?
- Synartro is headquartered in Uppsala, SE.